Sarclisa (isatuximab-irfc) is considered medically necessary for members 18
years of age or older who meet the following criteria:
Diagnosis of multiple
Have received at least
two other therapies, including Revlimid and a proteasome inhibitor (e.g.
Velcade, Ninlaro, Kyprolis);
Will be used in
combination with Pomalyst and dexamethasone;
Prescribed by or in
consultation with an oncologist.